Log In
Print
BCIQ
Print
Print this Print this
 

Moxetumomab pasudotox (CAT-8015)

  Manage Alerts
Collapse Summary General Information
Company AstraZeneca plc
DescriptionMurine anti-CD22 antibody variable fragment fused to PE38
Molecular Target CD22
Mechanism of ActionBinds CD22; Antibody
Therapeutic ModalityBiologic: Antibody

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Get a free BioCentury trial today